-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -- DUBLIN and BRIDGEWATER, N.J., Aug. 30, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted three sub-analyses from the REDUCE-IT® trial describing the impact of VASCEPA®/VAZKEPA® (icosapent ethyl - IPE) administration on cardiovascular disease (CVD) risk associated with Cardiovascula

MADRID — Novartis’ cholesterol-cutting medicine Leqvio swiftly improved high-risk patients’ lipid levels when added to standard of care, according to data presented Saturday at the annual meeting of the European Society of Cardiology. The Phase 4 trial, called V-DIFFERENCE, signed up 1,770 patients with high cholesterol who were at high or very high cardiovascular risk and had not yet reached the guideline-recommended levels of LDL-C, also called “bad” cholesterol. They were given an injection o

MADRID — Ionis Pharmaceuticals’ Tryngolza reduced triglycerides in patients with moderately high levels of these fat molecules in a late-stage test, according to data presented Saturday at the annual meeting of the European Society of Cardiology in Madrid. Results from the study, dubbed ESSENCE–TIMI 73b, were being monitored because of what they might mean for a more important trial of the drug: A late-stage test in patients with severe hypertriglyceridemia, for which data are expected in Septem

MADRID — Alnylam Pharmaceuticals said it will start a Phase 3 cardiovascular outcomes trial of its hypertension therapy zilebesiran this year, despite data showing the drug failed in a mid-stage study. Called KARDIA-3, the Phase 2 trial looked at zilebesiran’s ability to reduce blood pressure in patients with uncontrolled hypertension and high cardiovascular risk, who were on two or more background blood pressure drugs. Results, presented Saturday at the European Society of Cardiology congress i

MADRID — Pivotal data on AstraZeneca’s blood pressure pill baxdrostat look good enough for approval, but competing in the market might be a harder ask as the company prepares for a potential match against another new drug from Mineralys Therapeutics. The three-month blood pressure data presented Saturday showed a strong effect in patients with uncontrolled or resistant hypertension, forms of high blood pressure that do not respond to standard treatment. Patients given the higher dose of baxdrost

Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that primary results from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capaci

Welcome to another edition of Endpoints Weekly, and happy Labor Day weekend! I’ve returned from vacation and am ready to help you get your weekend started. Let’s get into the headlines. We had a lot of news out of Washington, DC this week, including growing turmoil at the CDC, where the Trump administration pushed out Director Susan Monarez just a few weeks after she was confirmed by the Senate. Reports indicated that HHS Secretary Robert F. Kennedy Jr. pressured Monarez to change the agency’s g

Bolstering Sanofi's immunology and inflammation (I&I) growth aspirations, the FDA on Friday approved the French pharma's Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The nod lends credence to Sanofi's $3.7-billion purchase of Principia Biopharma to gain the asset in 2020, as Wayrilz now represents a potential key growth driver for its I&I pipeline — an area the drugmaker is increasingly

MADRID — Cytokinetics believes its cardiac myosin inhibitor aficamten could become the new standard of care in a heart muscle disorder following the release of full data from a late-stage trial. The MAPLE-HCM study compared aficamten with beta blockers, the generic drugs used to treat a condition known as obstructive hypertrophic cardiomyopathy (oHCM). Patients with this condition have a thickened heart muscle and, therefore, difficulty pumping blood. Full data, presented Saturday at the Europea

August 30, 2025 2:45 am ET Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published in The Lancet RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results evaluating VERQUVO ® (vericiguat) in adult patients with stable chronic heart failure and reduced ejection fraction (HFrEF). The Phase 3 VICTOR trial comparing the